Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job

Workshop

Good Laboratory Practices (GLPs): Fundamentals, Regulatory Trends and Best Practices


Speakers: Lisa Helmonds, Vice President, MWA Consulting, Inc.
Organizers:
Date: 2017-10-24
Time: 8:30-12:00 Pacific Time
Registration fee: (USD): Regular: $125; Academic: $75; For unemployed or students: $25; For major-sponsor rep (incl lunch): $0; For vendor-show reps: $25
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date: (4)Intertek; MicroConstants; PHARMout Laboratories; Sekisui XenoTech, LLC
Registration: http://www.PBSS.org
Registration deadline:2017-10-22  (it will close sooner if the seating cap is reached)

About the Topic

This workshop will include a discussion on the history of Good Laboratory Practices (GLP) regulations, the importance of the regulations, key definitions, areas covered by the GLPs, a review of the regulations, examples of misconduct and, potential FDA actions.  After completing this workshop, participants should be able to understand the origin, purpose, and expectations of the GLP regulations.

8:45-9 am     PBSS Welcome & Workshop Overview

9-9:30 am     History of GLP Regulations

9:30-9:45 am    Areas Covered by GLPs

9:45-10 am    Key Definitions

10-10:15 am     Break & Vendor Show

10:15-11:15 am     Important Aspects of GLPs

  • Subpart A: General Provisions
  • Subpart B: Organization and Personnel
  • Subparts C & D: Facilities and Equipment
  • Subpart E: Testing Facilities Operations
  • Subpart F: Test and Control Articles
  • Subpart G: Protocol
  • Subpart J: Records and Reports
  • Subpart K: Disqualification

11:15 -11:30 am     FDA Actions and Misconduct

11:30-12 pm     Q & A

 


About the Speakers

Lisa Helmonds has over 30 years of experience in Manufacturing and Quality Assurance in the pharmaceutical, biotechnology and medical device industries. She has extensive GXP knowledge, has held positions as a manufacturing chemist and QA manager/director as an FTE and as a consultant with several startups and large companies such as Syva, Syntex, Roche Bioscience, Alza, Shire, Gilead, along with many others and she understands the challenges facing the industry.  She holds a BS in Zoology and minor in Chemistry from the University of Rhode Island and an MBA from Santa Clara University. She is currently Vice President of MWA Consulting, Inc. where she provides consulting services to MWA clients.


2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Online Workshop] Career Transition for Research Scientists
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
©Pharmaceutical & BioScience Society, International; Last Modified: 3/28/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Submit a Text Ad